U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H26N2.H2O4S
Molecular Weight 332.4605
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SPARTEINE SULFATE ANHYDROUS

SMILES

C1CCN2C[C@]3([H])C[C@@]([H])(CN4CCCC[C@]34[H])[C@]2([H])C1.OS(=O)(=O)O

InChI

InChIKey=FCEHFCFHANDXMB-UMEYXWOPSA-N
InChI=1S/C15H26N2.H2O4S/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17;1-5(2,3)4/h12-15H,1-11H2;(H2,1,2,3,4)/t12-,13-,14-,15+;/m0./s1

HIDE SMILES / InChI

Molecular Formula H2O4S
Molecular Weight 98.0796
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C15H26N2
Molecular Weight 234.3809
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including http://www.ndrugs.com/?s=spal

Sparteine is a class 1a antiarrhythmic agent; a sodium channel blocker. It is the predominant alkaloid in Lupinus mutabilis, and is thought to chelate the bivalents calcium and magnesium. It is not FDA approved for human use as an antiarrhythmic agent. It is also used as a chiral base in organic chemistry, and as a ligand in organic chemical synthesis. Marketed under the brand name Spal in Taiwan and Sparteine in Brazil.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
168.8 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Spal

Approved Use

Indications: arrhythmias
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
117.8 min
200 mg single, intravenous
dose: 200 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SPARTEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
117.45 min
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SPARTEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
50%
single, unknown
SPARTEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates.
2001 Aug
Scope of enantioselective palladium(II)-catalyzed aerobic alcohol oxidations with (-)-sparteine.
2003 May 30
Patents

Patents

Sample Use Guides

A single 100 mg oral dose of sparteine and a single 40 mg oral dose of dextromethorphan were administered on two occasions to 12 patients
Route of Administration: Oral
In Vitro Use Guide
Sparteine (20 uM) produced also remarkable inhibitions in the uptake of [3H]-histamine by astrocytes from rat brain.
Substance Class Chemical
Created
by admin
on Sat Jun 26 13:43:36 UTC 2021
Edited
by admin
on Sat Jun 26 13:43:36 UTC 2021
Record UNII
3D76XVF9R0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SPARTEINE SULFATE ANHYDROUS
WHO-DD  
Common Name English
NSC-143087
Code English
SPARTEINE SULFATE ANHYDROUS [WHO-DD]
Common Name English
SPARTEINE SULPHATE ANHYDROUS
Common Name English
Code System Code Type Description
FDA UNII
3D76XVF9R0
Created by admin on Sat Jun 26 13:43:37 UTC 2021 , Edited by admin on Sat Jun 26 13:43:37 UTC 2021
PRIMARY
PUBCHEM
23616742
Created by admin on Sat Jun 26 13:43:37 UTC 2021 , Edited by admin on Sat Jun 26 13:43:37 UTC 2021
PRIMARY
CAS
299-39-8
Created by admin on Sat Jun 26 13:43:37 UTC 2021 , Edited by admin on Sat Jun 26 13:43:37 UTC 2021
PRIMARY
ECHA (EC/EINECS)
206-078-4
Created by admin on Sat Jun 26 13:43:37 UTC 2021 , Edited by admin on Sat Jun 26 13:43:37 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY